Amsterdam researchers recently published an investigation of fecal microbiota transplantation (FMT) for the treatment of ulcerative colitis (UC). The TURN trial — Transplantation of feces in Ulcerative colitis; Returning Nature’s homeostasis — was a double-blind randomized trial with 48 subjects who had mild to moderatively active UC.
Participants received either a healthy donor’s feces or their own feces (i.e. autologous FMT) via naso-duodenal tube.
No significant difference was observed between groups. In the per protocol analysis, 41.2% of patients in the donor group and 25% of controls achieved the primary endpoint, which was clinical remission of UC. Serious adverse events occurred in 4 patients but these were not considered related to the FMT.
Patients who responded to FMT donor treatment showed a shift toward a donor-like microbiota composition. The microbiota of responders had distinct features from that of nonresponders after FMT.
This study contrasts with a recent study from Canada (covered here on GMFH) in which 24% of the FMT group and 5% of the placebo group achieved remission.
In the Canadian study, the placebo group received a water treatment, while in the Dutch study the placebo group received autologous FMT. Mode of administration was also different — enema and naso-duodenal tube, respectively. Also, while the Canadian study showed a possible donor effect, this was not assessed in the Dutch study because of low numbers in each subgroup.
Rossen NG, et al. (2015) Findings from a Randomized Controlled Trial of Fecal Transplantation for Patients with Ulcerative Colitis. Gastroenterology DOI: http://dx.doi.org/10.1053/j.gastro.2015.03.045
Besides bacteria, researchers have begun to study archaea, fungi, protozoa and viruses of the ...
One way by which the gut microbiome shapes host physiology is by modulating immune responses. ...
Although nowadays diet plays only a small part in published guidelines for managing ...